<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271804</url>
  </required_header>
  <id_info>
    <org_study_id>04-381</org_study_id>
    <nct_id>NCT00271804</nct_id>
  </id_info>
  <brief_title>Study of Velcade and Thalidomide in Patients With Myelodysplasia</brief_title>
  <official_title>Phase I Dose Escalation Trial of Bortezomib in Combination With Thalidomide in Patients With Myelodysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what the maximal tolerated dose of Velcade can be&#xD;
      given with thalidomide in patients with myelodysplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial studies using Velcade in myelodysplasia with early results demonstrating that 35% had&#xD;
      a partial response and 25% had stable disease. The combination of Velcade and thalidomide has&#xD;
      been studied in patients with multiple myeloma, but not in patients with myelodysplasia. The&#xD;
      CRR in the MM patients was 22%, with a good safety profile.&#xD;
&#xD;
      This is a phase 1, prospective, open-label, dose escalation study to evaluate the DLT and MTD&#xD;
      of velcade with given in combination with thalidomide in patients with myelodysplasia.&#xD;
      Treatment will be given as an outpatient. Patients will receive 4 days of Velcade (days 1, 4,&#xD;
      8, 11) and 21 days of thalidomide 50 mg/day for each 21 day cycle. There will be 3 cohorts of&#xD;
      3-6 patients each, plus 10 additional patients. The tree dose levels ill be 0.7, 1.0 and 1.3&#xD;
      mg/m2. Patients may continue to be treated up to 6 cycles. Cycles 2-6 will start within 2&#xD;
      weeks of completion of the previous cycle. Disease response will be evaluated after cycle 3&#xD;
      and 6.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    New study with lenalidomide pending&#xD;
  </why_stopped>
  <start_date>June 2005</start_date>
  <completion_date>April 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to establish the maximally tolerated dose of bortezomib that can be administered with thalidomide in patient with myelodysplasia.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess efficacy in terms of the number of patients attaining a 50% reduction in blast percentage, or 50% reduction in number of red blood cell and/or platelet transfusions.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the toxicity profile of bortezomib when used in combination with thalidomide for patients with myelodysplasia.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the relationship between NF-kB expression and clinical response to bortezomib and thalidomide.</measure>
  </secondary_outcome>
  <enrollment>28</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Myelodysplastic syndrome with a IPSS score of 0.5 or greater&#xD;
&#xD;
          -  May have had prior chemo/radiotherapy for another malignancy or myelodysplasia&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  Life expectancy greater than 3 months&#xD;
&#xD;
          -  Total bilirubin &lt;/+ 2xULN&#xD;
&#xD;
          -  ALT and AST &lt;/+ 3xULN&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; 30 ml/min&#xD;
&#xD;
          -  Use of appropriate method of contraception during the study&#xD;
&#xD;
          -  ANC &gt; 0.5 x 10(9)&#xD;
&#xD;
          -  Platelet count &gt; 30 x 10(9)&#xD;
&#xD;
          -  Consideration of treatment with 5 azacytidine is encouraged by not required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ejection fraction &lt; 40%&#xD;
&#xD;
          -  myocardial infarction within 6 months of enrollment of New York Heart Association&#xD;
             Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular&#xD;
             arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction&#xD;
             system abnormalities&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to enrollment&#xD;
&#xD;
          -  &gt;/= grade 2 peripheral neuropathy within 14 days prior to enrollment&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Serious medical or psychiatric illness that could potentially interfere with the&#xD;
             completion of treatment&#xD;
&#xD;
          -  Hypersensitivity to bortezomib, boron, or mannitol&#xD;
&#xD;
          -  Received an investigational drug within 14 days of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Ballen, M</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital, Harvard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>December 30, 2005</study_first_submitted>
  <study_first_submitted_qc>December 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2006</study_first_posted>
  <last_update_submitted>March 7, 2008</last_update_submitted>
  <last_update_submitted_qc>March 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Karen Ballen</name_title>
    <organization>Massachusetts general Hospital</organization>
  </responsible_party>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Myelodysplasia</keyword>
  <keyword>MDS</keyword>
  <keyword>Velcade</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Bortezomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

